Novo Nordisk Reports Net Profit

Novo Nordisk A/S's (NOVO-B.KO) diabetes treatment Victoza has had a positive reception since it was launched on a number of European markets in July, Chief Executive Lars Rebien Sorensen said at a conference call Thursday, following the Danish pharmaceutical company's second-quarter report , Wall Street Journal reports.

However, the world's top supplier of insulin said net profit in April through June reached almost 3 billion kroner ($580 million), up from about 2.5 billion kroner in the same period in 2008. Sales increased to 13 billion kroner from 11.1 billion kroner , Los Angeles Times reports.

Meanwhile, his remarks came after the company said in its second-quarter earnings report that it was in a "constructive dialogue" with the FDA on Victoza.

Brandgaard said that the global insulin markets were growing more slowly than the company previously expected , Reuters reports.

Subscribe to Pravda.Ru Telegram channel, Facebook, Twitter, YouTube, RSS!

Author`s name Editorial Team